COPA-R-CHOP

DLBCL 1st line

R-CHOP + Copa

Copanlisib

offen

GO29781

Roche/Genentech

relapsed oder refraktär NHL/CLL

Mosunetuzumab mono vs Mosunetuzumab mit Atezolizumab

BTCT4465A u Atezolizumab

offen, Slotanfrage

NIVEAU

DLBCL rez.

R-GemOx +/- Nivolumab

Nivolumab

offen

AERN

HD rez.

Nivolumab

offen

MCL Register

MCL

GLA Lymphome

follikuläre Lymphome & MZL

GAZAI

FL Frühstadien

Obinutuzumab + 4Gy

Obinutuzumab + 4Gy

offen

ALTERNATIVE C

FL 1. Linie

Obinutuzumab + Copanlisib

Copanlisib

offen

COUP-1

Uniklinik Ulm

Marginalzonen-Lymphom

Primärtherapie

Copanlisib (IMP) + Ritux

offen

PAVO CCTL019A2205B

Novartis

Ref./ Relapsed Follicular Lymphoma

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy

CTL019 (tisagenlecleucel)

Initiierung hat stattgefunden

CHARLY Trial

Lymphom Non-Hodgkin

Haploident. Transplantation

Cyclophosphamid

offen

GHSG _ Allo bei HL

Hodgkin Lymphom / Transplantation

posttransplantations Strategien

Brentuximab in Erhaltung + Konsolidierung

offen

Aaron

Ref./ Relaps. New diagn. AML

Relatlimab with Nivolumab in Comb. 5-Azacytidine by relapsed / refractory or newly diagnosed AML

Relatlimab + Nivolumab + 5-Azacitidine

in Einreichung

AMG330 (20120252)

Amgen

AML

Rezidiv-Monotherapie, MRD-Kohorte

AMG330

offen, Slotanfrage

AMG673

Amgen

AML (relapsed/refractory)

AMG 673 Administered as Short Term Intravenous Infusion

offen

BLAST Halle

AML

Cytarabin + BL 8040 vs. Placebo

BL 8040

offen

WP2004

F. Hoffmann- La. Roche LTD

AML hematologic and molecular relapse

DOSE ESCALATION OF RO7283420 IN AML

bispez. AK

offen (Greenlight ab 24.08.2021)

IMCgp (immunocore)

Immunocore

Uveales Melanom

IMCgp100 vs Investigator choice

IMCgp100

offen

EWALL BOLD

Universität Frankfurt

ALL

Blinatumomab

offen

TRANSCEND JCAR017 BCM-001

Celgene / BMS

aggr. B-Zell NHL

CAR-T-Cells bei aggr. B-Zell Lymphom

JCAR017

offen, Sponsor meldet Slots

AMG 427

Amgen

AML (FLAG 3 pos)

Bite AK (Flag 3) short term infus.

AMG 427

offen

TEAM-Trial

AML

Acute Myeloid Leukemia

Borte+Cyta+Gemtu+Pegfilg.

offen

APOLLO

Universität Dresden

APL

ATO/ATRA

ATO/ATRA

offen

BIBF 1120

AML

safety and efficacy of nintendanib

Nintendanib

offen

GMALL Register

Universität Frankfurt

ALL

offen

GMALL 08/2013 (Prof. Spiekermann)

Universität Frankfurt

ALL/LBL

Therapieoptimierung

Nelarabin

offen

CML Register (CML VI)

Universität Heidelberg

CML

Register

offen

AML Register

Universität Münster 

AML

Register

offen

HD21

Uniklinik Köln

HD

offen für +61 Jahre

COVIM

Charité Berlin

Covid19-Impfstudie

offen

DSMMXVII

MM 1st line

Elotuzumab, Carfilzomib, Lenalidomit, Dexamethason

Elotuzumab

offen

JCAR-017-FOL-001

Celgne / BMS

Refractory indolent B-Cell- Non-Hodgin Lymphome

Car-T-Cell

Car-T-Cell

offen